Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Ultragenyx Pharmaceutical (RARE) Accumulated Depreciation & Amortization (2016 - 2025)

Ultragenyx Pharmaceutical has reported Accumulated Depreciation & Amortization over the past 11 years, most recently at $136.0 million for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 21.43% to $136.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $136.0 million through Dec 2025, up 21.43% year-over-year, with the annual reading at $136.0 million for FY2025, 21.43% up from the prior year.
  • Accumulated Depreciation & Amortization was $136.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $112.0 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $136.0 million in Q4 2025 and troughed at $50.0 million in Q4 2021.
  • The 5-year median for Accumulated Depreciation & Amortization is $83.4 million (2023), against an average of $89.0 million.
  • Year-over-year, Accumulated Depreciation & Amortization surged 34.29% in 2024 and then increased 21.43% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $50.0 million in 2021, then rose by 26.67% to $63.4 million in 2022, then skyrocketed by 31.59% to $83.4 million in 2023, then surged by 34.29% to $112.0 million in 2024, then increased by 21.43% to $136.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Accumulated Depreciation & Amortization are $136.0 million (Q4 2025), $112.0 million (Q4 2024), and $83.4 million (Q4 2023).